WO2009029883A3 - Procédés et compositions permettant de moduler les lymphocytes t - Google Patents

Procédés et compositions permettant de moduler les lymphocytes t Download PDF

Info

Publication number
WO2009029883A3
WO2009029883A3 PCT/US2008/074908 US2008074908W WO2009029883A3 WO 2009029883 A3 WO2009029883 A3 WO 2009029883A3 US 2008074908 W US2008074908 W US 2008074908W WO 2009029883 A3 WO2009029883 A3 WO 2009029883A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
cells
compositions
methods
dysregulation
Prior art date
Application number
PCT/US2008/074908
Other languages
English (en)
Other versions
WO2009029883A2 (fr
Inventor
Andrew Chan
Jung-Hua Yeh
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to CA2715305A priority Critical patent/CA2715305A1/fr
Priority to US12/675,763 priority patent/US20100247430A1/en
Priority to BRPI0817052 priority patent/BRPI0817052A2/pt
Priority to MX2010002028A priority patent/MX2010002028A/es
Priority to CN200880114152A priority patent/CN101854949A/zh
Priority to AU2008292854A priority patent/AU2008292854A1/en
Priority to EP08828178A priority patent/EP2190468A2/fr
Priority to JP2010523177A priority patent/JP2010538018A/ja
Publication of WO2009029883A2 publication Critical patent/WO2009029883A2/fr
Publication of WO2009029883A3 publication Critical patent/WO2009029883A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne des procédés et des compositions utiles pour moduler les lymphocytes T et les troubles associés à leur dérèglement.
PCT/US2008/074908 2007-08-30 2008-08-29 Procédés et compositions permettant de moduler les lymphocytes t WO2009029883A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2715305A CA2715305A1 (fr) 2007-08-30 2008-08-29 Procedes et compositions permettant de moduler les lymphocytes t
US12/675,763 US20100247430A1 (en) 2007-08-30 2008-08-29 Methods and Compositions for Modulating T Cells
BRPI0817052 BRPI0817052A2 (pt) 2007-08-30 2008-08-29 Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo.
MX2010002028A MX2010002028A (es) 2007-08-30 2008-08-29 Metodos y composiciones para modular celulas t.
CN200880114152A CN101854949A (zh) 2007-08-30 2008-08-29 用于调控t细胞的方法和组合物
AU2008292854A AU2008292854A1 (en) 2007-08-30 2008-08-29 Methods and compositions for modulating T cells
EP08828178A EP2190468A2 (fr) 2007-08-30 2008-08-29 Procédés et compositions permettant de moduler les lymphocytes t
JP2010523177A JP2010538018A (ja) 2007-08-30 2008-08-29 Ｔ細胞を調節するための方法及び組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96905907P 2007-08-30 2007-08-30
US60/969,059 2007-08-30
US3402108P 2008-03-05 2008-03-05
US61/034,021 2008-03-05

Publications (2)

Publication Number Publication Date
WO2009029883A2 WO2009029883A2 (fr) 2009-03-05
WO2009029883A3 true WO2009029883A3 (fr) 2009-11-05

Family

ID=39929595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074908 WO2009029883A2 (fr) 2007-08-30 2008-08-29 Procédés et compositions permettant de moduler les lymphocytes t

Country Status (10)

Country Link
US (1) US20100247430A1 (fr)
EP (1) EP2190468A2 (fr)
JP (1) JP2010538018A (fr)
KR (1) KR20100067089A (fr)
CN (1) CN101854949A (fr)
AU (1) AU2008292854A1 (fr)
BR (1) BRPI0817052A2 (fr)
CA (1) CA2715305A1 (fr)
MX (1) MX2010002028A (fr)
WO (1) WO2009029883A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2069793T3 (en) 2006-08-29 2017-04-24 Oxford Biotherapeutics Ltd IDENTIFICATION OF PROTEIN IN CONNECTION WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER
HUE034196T2 (en) 2009-03-05 2018-02-28 Squibb & Sons Llc Fully human antibodies specific for CADM1
KR101317507B1 (ko) * 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
WO2013000021A1 (fr) * 2011-06-29 2013-01-03 Cellestis Limited Essai à sensibilité accrue d'une réponse immunitaire à médiation cellulaire
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
SG11201701191WA (en) * 2014-07-18 2017-03-30 Univ Kyoto Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
EP3215168B1 (fr) 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Modification de l'expression génétique dans des lymphocytes t modifiés et utilisations associées
WO2016154341A1 (fr) * 2015-03-23 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Utilisations médicales d'agonistes de crtam
JP6536944B2 (ja) * 2015-06-05 2019-07-03 株式会社膠原病研究所 自己免疫疾患の発症に関与する細胞を判定する方法及びその利用
KR20200100858A (ko) * 2015-12-23 2020-08-26 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
CA3079313A1 (fr) * 2017-11-02 2019-05-09 Oxford Biotherapeutics Ltd Anticorps et procedes d'utilisation associes
WO2021092593A1 (fr) * 2019-11-08 2021-05-14 The University Of North Carolina At Chapel Hill Utilisation d'antagonistes pour augmenter la fonction t-car dans des tumeurs solides
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
WO2023274286A1 (fr) * 2021-06-30 2023-01-05 南京圣和药业股份有限公司 Anticorps anti-crtam et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012530A2 (fr) * 2003-07-25 2005-02-10 Amgen Inc. Antagonistes et agonistes de ldcam et procedes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012530A2 (fr) * 2003-07-25 2005-02-10 Amgen Inc. Antagonistes et agonistes de ldcam et procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VICARI A P ET AL: "Mouse NK1.1+ T cells: a new family of T cells", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 17, no. 2, 1 February 1996 (1996-02-01), pages 71 - 75, XP004034656, ISSN: 0167-5699 *
YEH JUNG-HUA ET AL: "Regulation of a late phase of T cell polarity and effector functions by Crtam", CELL, vol. 132, no. 5, March 2008 (2008-03-01), pages 846 - 859, XP009121986, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
CA2715305A1 (fr) 2009-03-05
CN101854949A (zh) 2010-10-06
US20100247430A1 (en) 2010-09-30
AU2008292854A1 (en) 2009-03-05
MX2010002028A (es) 2010-03-15
WO2009029883A2 (fr) 2009-03-05
EP2190468A2 (fr) 2010-06-02
BRPI0817052A2 (pt) 2015-03-24
KR20100067089A (ko) 2010-06-18
JP2010538018A (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2009029883A3 (fr) Procédés et compositions permettant de moduler les lymphocytes t
WO2009076676A3 (fr) Compositions et méthodes de production d'isoprène
WO2008033408A3 (fr) Procédés d'identification de composés qui modulent la signalisation cellulaire et procédés employant de tels composés
WO2008014008A3 (fr) Compositions et procédés pour moduler l'angiogenèse
WO2010011407A3 (fr) Procédés de génération de substrats souples modelés et leurs utilisations
WO2011142858A3 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
WO2008110308A3 (fr) Nouveaux herbicides
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2010077740A3 (fr) Nouveaux composés antiviraux, compositions et procédés d'utilisation
WO2008066630A3 (fr) Procédés de reprogrammation de cellules somatiques adultes, et leurs utilisations
WO2006105338A3 (fr) Variants fc presentant des proprietes optimisees
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2009039307A3 (fr) Hydrogels et procédés de production et d'utilisation de ceux-ci
WO2007014930A3 (fr) Copolymeres de polyammonium-polysiloxane
UA101346C2 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды
WO2010065969A8 (fr) Scfc de liaison à sparc
WO2009042114A3 (fr) Dérivés de phénazine et leurs utilisations
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2008082987A3 (fr) Protections et méthodes pour appareils de mesure de substances à analyser
WO2008042216A3 (fr) PROCÉDÉS, matÉriel et compositions pour gÉNÉrer de nouveaux follicules pileux et faire pousser les cheveux
WO2008134668A3 (fr) Précurseurs thermolabiles
EP2179598A4 (fr) Localisation sécurisée pour des réseaux 802.11 avec une granularité précise
WO2005107461A3 (fr) Modulation de la fonction lymphatique
WO2008027600A3 (fr) Compositions d'imatinib
WO2008086228A3 (fr) Réseaux et procédés de formation de motif de cellule guidée

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114152.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828178

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2715305

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 203868

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008292854

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002028

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010523177

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008292854

Country of ref document: AU

Date of ref document: 20080829

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107006812

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008828178

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12675763

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0817052

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100226